AlphaVax, Inc.

The latest Ebola epidemic, which the WHO says has now claimed more than 9,600 lives, has focused attention on the long-term need for a prophylactic vaccine to prevent future outbreaks of this size. Th

Novartishas acquired an investigational cytomegalovirus (CMV) vaccine programme from the US-based vaccine developer AlphaVax for $20 million. The acquisition of the CMV programme adds to Novartis's ea

by Robert Neil and Mary Thompson The aging US population is fueling increased demand in a number of health care markets, and nowhere are these changing demographic forces more evident than in the area

Viral vaccine vectors with advantages For well over a decade, researchers at the University of North Carolina (UNC) virology labs and the US Army Medical Research Institute of Infectious Diseases